Riding the waves: evidence for a beneficial effect of increased water intake in autosomal dominant polycystic kidney disease patients?

被引：3
作者：
Meijer, E. [1 ]
Casteleijn, N. F. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2014年 / 29卷 / 09期
关键词：
SURROGATE MARKER; VASOPRESSIN; COPEPTIN; PROGRESSION; SECRETION; DECLINE; GROWTH; FLUID; PCK;
D O I：
10.1093/ndt/gfu054
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：1615 / 1617
页数：3
相关论文
共 21 条
[1]   Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects [J].
Bankir, L .
CARDIOVASCULAR RESEARCH, 2001, 51 (03) :372-390
[2]   A Pilot Clinical Study to Evaluate Changes in Urine Osmolality and Urine cAMP in Response to Acute and Chronic Water Loading in Autosomal Dominant Polycystic Kidney Disease [J].
Barash, Irina ;
Ponda, Manish P. ;
Goldfarb, David S. ;
Skolnik, Edward Y. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (04) :693-697
[3]   Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells [J].
Belibi, FA ;
Reif, G ;
Wallace, DP ;
Yamaguchi, T ;
Olsen, L ;
Li, H ;
Helmkamp, GM ;
Grantham, JJ .
KIDNEY INTERNATIONAL, 2004, 66 (03) :964-973
[4]   Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease [J].
Boertien, Wendy E. ;
Meijer, Esther ;
de Jong, Paul E. ;
Bakker, Stephan J. L. ;
Czerwiec, Frank S. ;
Struck, Joachim ;
Oberdhan, Dorothee ;
Shoaf, Susan E. ;
Krasa, Holly B. ;
Gansevoort, Ron T. .
KIDNEY INTERNATIONAL, 2013, 84 (06) :1278-1286
[5]   Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, With Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results From the CRISP Cohort [J].
Boertien, Wendy E. ;
Meijer, Esther ;
Li, Jie ;
Bost, James E. ;
Struck, Joachim ;
Flessner, Michael F. ;
Gansevoort, Ron T. ;
Torres, Vicente E. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (03) :420-429
[6]   Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease [J].
Boertien, Wendy E. ;
Meijer, Esther ;
Zittema, Debbie ;
van Dijk, Marjan A. ;
Rabelink, Ton J. ;
Breuning, Martijn H. ;
Struck, Joachim ;
Bakker, Stephan J. L. ;
Peters, Dorien J. M. ;
de Jong, Paul E. ;
Gansevoort, Ron T. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (11) :4131-4137
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   Progressive hepatic failure secondary to adult polycystic kidney disease [J].
Elias, TJ ;
Bannister, KM ;
Clarkson, AR ;
Faull, RJ .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1999, 29 (02) :282-283
[9]   Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist [J].
Gattone, VH ;
Wang, XF ;
Harris, PC ;
Torres, VE .
NATURE MEDICINE, 2003, 9 (10) :1323-1326
[10]   Diagnosis and management of polycystic liver disease [J].
Gevers, Tom J. G. ;
Drenth, Joost P. H. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (02) :101-108
123